

Hanoi, 05 May 2026

**RESOLUTION
OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026**

THE GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY

Pursuant to:

- Law on Enterprises No. 59/2020/QH14, adopted by the National Assembly of the Socialist Republic of Viet Nam on 17 June 2020;
- The Charter on Organization and Operation of Nghe An Pharmaceutical - Medical Supplies Joint Stock Company (the "Company");
- The Meeting Minutes of the 2026 Annual General Meeting of Shareholders of the Company dated 05 May 2026.

RESOLUTION

Article 1. The General Meeting of Shareholders ("GMS") of Nghe An Pharmaceutical – Medical Supplies Joint Stock Company (the "Company") has voted to approve the following resolutions:

1. **RESOLUTION 1:** The GMS approves the report of the Company's Board of Management on the production and business performance ("P&B") for 2025 and the production and business plan for 2026.
2. **RESOLUTION 2:** The GMS approves the audited financial statements ("FS") of the Company for the year 2025.
3. **RESOLUTION 3:** The GMS approves the report on the operational results of the Board of Directors ("BOD") for 2025 and the orientations and operation plan for 2026.
4. **RESOLUTION 4:** The GMS approves the report of the Supervisory Board ("SB") submitted to the 2026 Annual General Meeting of Shareholders.
5. **RESOLUTION 5:** The GMS approves the finalization of remuneration for members of the BOD and the SB for 2025, and the remuneration plan for 2026, in accordance with Submission No. 21/2026/TTr-HĐQT dated 09 April 2026 of the Board of Directors, specifically as follows:
 - 5.1 The finalized remuneration for members of the BOD and SB of the Company for 2025 (inclusive of personal income tax, covering 12 months of remuneration and 01 additional month of remuneration for the Lunar New Year) amounts to VND 182,000,000, of which:
 - Total remuneration for the Board of Directors in 2025: VND 117,000,000 per year;
 - Total remuneration for the Supervisory Board in 2025: VND 65,000,000 per year.
 - 5.2 The estimated remuneration for members of the BOD and SB of the Company for 2026 is as follows:
 - Board of Directors:
 - + Chairman of the Board of Directors: VND 5,000,000 per month;

+ Member of the Board of Directors: VND 2,000,000 per person per month.

- Supervisory Board:

+ Head of the Supervisory Board: VND 2,000,000 per month;

+ Member of the Supervisory Board: VND 1,500,000 per person per month.

The total estimated remuneration for the BOD and Supervisory Board in 2026 is VND 182,000,000 (inclusive of personal income tax, covering 12 months of remuneration and 01 additional month of remuneration for the Lunar New Year).

6. **RESOLUTION 6:** The GMS approves the plan for distribution of profit after tax for 2025 in accordance with Submission No. 20/2026/TTr-HĐQT dated 09 April 2026 of the Board of Directors, specifically as follows:

No.	Item	Amount (VND)
I	Undistributed profit after tax	11.958.162.700
1	Accumulated undistributed profit after tax up to the end of the previous period	8.733.814.005
2	Undistributed profit after tax for 2025	3.224.348.695
II	Appropriation to funds in 2026	
1	Reward and welfare fund (10% × profit after tax of 2025)	322.434.870
2	Development investment fund (25% × profit after tax of 2025)	806.087.174
3	Dividend distribution	0
III	Remaining profit	10.829.640.656

7. **RESOLUTION 7:** The GMS approves the authorization of the Board of Directors to decide on the selection of an independent auditing firm to conduct the audit of the Company's financial statements for 2026, in accordance with Submission No. 26/2026/TTr-BKS dated 09 April 2026 of the Supervisory Board.
8. **RESOLUTION 8:** The GMS approves the amendment of the Company's Charter on organization and operation in accordance with Submission No. 22/2026/TTr-HĐQT dated 09 April 2026 of the Board of Directors.
9. **RESOLUTION 9:** The General Meeting of Shareholders approves the dismissal and additional election of members of the Supervisory Board for the remaining term 2023–2028, as follows:
- Ms. Dang Thi Huong Lan ceases to hold the position of Supervisory Board member of the Company for the term 2023–2028;
 - Approval of the number of additional Supervisory Board members: The General Meeting approved the election of 01 additional Supervisory Board member to replace the resigned member
 - Ms. Tran Thi Cam Tu is elected as a Supervisory Board member of the Company for the remaining term 2023–2028.
10. **RESOLUTION 10:** The General Meeting of Shareholders fully authorizes the Board of Directors, and permits the Board of Directors to further delegate such authority to the Chairman of the Board of Directors or another member, to review, decide and organize the implementation of all matters approved by the General Meeting of Shareholders, as well as to review and decide on other matters falling within the authority of the General Meeting of Shareholders that arise and require resolution between two annual General Meetings, and to carry out all relevant procedures in accordance with applicable regulations.



All resolutions and authorizations approved by the 2026 Annual General Meeting of Shareholders shall take effect from the date of approval and shall remain valid for an indefinite duration until otherwise replaced by a subsequent decision of the General Meeting of Shareholders.

Điều 2: This Resolution shall take effect from the date of signing.

Shareholders, the Board of Directors, the Supervisory Board, the Board of Management, Heads of departments/divisions/branches/affiliated units of the Company, and all related individuals shall be responsible for the implementation of this Resolution./.

Nơi nhận:

- Shareholders of the Company (for information);
- Filed: Administration Office, Board of Directors.

ON BEHALF OF
THE GENERAL MEETING OF SHAREHOLDERS
CHAIRMAN OF THE BOARD OF DIRECTORS



NGUYEN VAN THANG





NGHE AN PHARMACEUTICAL –
MEDICAL MATERIAL AND EQUIPMENT
JOINT STOCK COMPANY

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

MINUTES OF THE ANNUAL GENERAL MEETING OF
SHAREHOLDERS 2026

Enterprise's name : Nghe An Pharmaceutical – Medical Material and Equipment
Joint Stock Company (“Company”)
Headquater : No. 16 Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe A
Province
Business Registration : 2900491298
No.
Time : From 08:00 a.m dated May 05, 2026
Location : Thang Loi Hotel, No. 200 Yen Phu Street, Tay Ho Ward, Hanoi,
Vietnam

A. Meeting's Agenda:

1. Report of the Board of Management on business performance in 2025 and business plan for 2026
2. Audited financial statements for 2025
3. Report of the Board of Directors (BOD) on 2025 activities and 2026 plan
4. Report of the Supervisory Board (SB)
5. Proposal on remuneration settlement for 2025 and plan for 2026 (BOD & SB)
6. Proposal on profit distribution for 2025
7. Proposal on selection of auditing firm for 2026
8. Proposal on amendment of the Company Charter
9. Proposal on dismissal and election of additional SB member (term 2023–2028)
10. Other matters (if any)
11. Approval of AGM Minutes and Resolution

B. MEETING PROCEEDINGS

I. OPENING OF THE GENERAL MEETING AND ATTENDEES

1. Opening of the General Meeting

The General Meeting heard the opening speech delivered by Ms. Lê Thị Duyên, on behalf of the Organizing Committee.

2. Attendees of the General Meeting

2.1. Shareholders

All shareholders holding shares of the Company as of the record date of 06 April 2026.

2.2. Incumbent Members of the Board of Directors

- Mr. Nguyễn Văn Thắng – Chairman of the Board of Directors

2.3. Incumbent Members of the Supervisory Board

- Mr. Đào Mạnh Hùng – Member of the Supervisory Board

2.4. Members of the Board of Management

- Mr. Trần Công Vinh – Deputy Director in charge of the Company
- Mr. Nguyễn Phi Hào – Chief Accountant

3. Report on Verification of Shareholder Eligibility

At 08:30 a.m., the General Meeting heard Mr. Nguyễn Trung Dũng – Member of the Shareholder Eligibility Verification Committee – present the report on the verification results.

- The total number of voting shares of the Company is:
 - 6,000,000 shares: according to the shareholder list finalized as of April 6, 2026, provided by VSD;
 - 15,000,000 shares: the number of voting shares currently in circulation as of April 6, 2026.

As of April 6, 2026, the Company is in the process of additionally registering the shares issued in the public offering of 9,000,000 shares to existing shareholders. Therefore, VSD has not yet updated this figure in the shareholder list finalized on April 6, 2026, resulting in a discrepancy between the shareholder list provided by VSD and the number of voting shares currently in circulation as of April 6, 2026.

- The total number of shareholders entitled to attend the meeting: 185 shareholders, holding a total of 6,000,000 shares, equivalent to 100% of the charter capital, according to the shareholder list finalized as of April 6, 2026, provided by VSD.
- Shareholders attending the Meeting in person and by proxy: 32 shareholders, representing ownership of 5,453,260 ordinary shares, equivalent to 90.8877% of the total shares entitled to attend the Meeting.
- Absent shareholders: 153 shareholders, representing ownership of 546,740 ordinary shares, equivalent to 9.1123% of the total shares entitled to attend the Meeting.

Pursuant to Law on Enterprises No. 59/2020/QH14 and the Charter on Organization and Operation of the Company, the number of shareholders attending in person and by proxy was sufficient to conduct the 2026 Annual General Meeting of Shareholders validly.

II. AGENDA OF THE GENERAL MEETING

1. Approval of the Presidium, Secretariat, and Vote-Counting Committee

1.1. Presidium

- Mr. Nguyen Van Thang – Chairman of the Board of Directors – Chairing of the Meeting;
- Mr. Tran Cong Vinh – Deputy Director in charge of the Company – Member of the Presidium.

1.2. Secretariat

- Mr. Chu Huy Tung – Head of the Secretariat
- Mr. Nguyen Phi Hao – Member

1.3. Vote-Counting Committee

- Ms. Le Thi Duyen – Head
- Mr. Nguyen Trung Dung – Member
- Mr. Nguyen Manh Tien – Member

Shareholders' comments: None

The General Meeting voted by raising voting cards to approve the above composition.

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

2. Approval of the Meeting Agenda and the Rules of Procedure

The General Meeting heard Mr. Nguyen Van Thang, Chairman of the Meeting, present the Meeting Agenda and Rules of Procedure for approval.

Shareholders' comments: None

The General Meeting voted by raising voting cards to approve the above composition.

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

3. Reports and Submissions Presented at the General Meeting

3.1. Presented by Mr. Tran Cong Vinh – Deputy Director in charge of the Company

- Report of the Board of Management on production and business performance in 2025 and the production and business plan for 2026;
- Audited financial statements of the Company for 2025.

Shareholders' comments: None

3.2. Presented by Mr. Nguyen Van Thang – Chairman of the Meeting, on behalf of the Board of Directors: Report on the operational results of the Board of Directors in 2025 and orientations and plans for 2026.

Shareholders' comments: None

3.3. Presented by Mr. Dao Manh Hung – Member of the Supervisory Board

- Supervisory Board Report submitted to the 2026 Annual General Meeting of Shareholders;
- Submission No. 26/2026/TTr-HĐQT dated 09/04/2026 regarding the selection of the auditor for the 2026 financial statements.

Shareholders' comments: None

3.4. Presented by Mr. Nguyen Van Thang – Chairman of the Meeting, Chairman of the Board of Directors:

- Submission No. 21/2026/TTr-HĐQT dated 09/04/2026 on approval of the finalization of remuneration for members of the Board of Directors and Supervisory Board in 2025 and remuneration plan for 2026;

- Submission No. 20/2026/TTr-HĐQT dated 09/04/2026 on the profit distribution plan for 2025.

Shareholders' comments: None

3.5. Presented by Mr. Tran Cong Vinh – Deputy Director in charge

- Submission No. 22/2026/TTr-HĐQT dated 09/04/2026 on amendments to the Company Charter;
- Submission No. 25/2026/TTr-HĐQT dated 09/04/2026 on dismissal and additional election of a Supervisory Board member for the remaining term 2023–2028.

Shareholders' comments: None

III. DISMISSAL AND ADDITIONAL ELECTION OF A SUPERVISORY BOARD MEMBER FOR THE REMAINING TERM 2023–2028

1. Approval of the dismissal: The General Meeting approved the dismissal of Ms. Dang Thi Huong Lan from the Supervisory Board for the term 2023–2028.

Shareholders' comments: None

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

2. Approval of the number of additional Supervisory Board members: The General Meeting approved the election of 01 additional Supervisory Board member to replace the resigned member.

Shareholders' comments: None

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

3. Approval of the list of candidates for election to the Supervisory Board for the remaining term 2023–2028.

- Ms. Tran Thi Cam Tu

Shareholders' comments: None

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

4. Approval of the election regulations: The General Meeting approved the election regulations for additional Supervisory Board members for the remaining term 2023–2028.

Shareholders' comments: None

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

5. Approval of the election method: The additional election was conducted by raising voting cards.

Shareholders' comments: None

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

6. Election results

- Ms. Tran Thi Cam Tu received 5,453,260 votes, equivalent to 100% of the total voting shares attending the Meeting.

- Accordingly, Ms. Tran Thi Cam Tu was elected as a Supervisory Board member for the remaining term 2023–2028.

Shareholders' comments: None

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

IV. APPROVAL OF RESOLUTIONS

After reviewing the reports and submissions, the General Meeting approved the following resolutions:

1. Resolution 1: Approval of the Board of Management's report on 2025 production and business results and the 2026 plan.

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

2. Resolution 2: Approval of the audited financial statements for 2025.

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

3. Resolution 3: Approval of the Board of Directors' operational report for 2025 and plan for 2026.

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

4. Resolution 4: Approval of the Supervisory Board Report to the 2026 AGM.

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

5. Resolution 5: Approval of remuneration finalization for 2025 and the remuneration plan for 2026:

5.1. Finalization of Remuneration for Members of the Board of Directors and the Supervisory Board of the Company for 2025: The finalized remuneration for members of the Board of Directors ("BOD") and the Supervisory Board ("SB") of the Company for the year 2025 (inclusive of personal income tax, covering 12 months of remuneration and 01 additional month of remuneration for the Lunar New Year) amounts to VND 182,000,000, of which:

- Total remuneration of the Board of Directors for 2025: VND 117,000,000 per year;
- Total remuneration of the Supervisory Board for 2025: VND 65,000,000 per year.

5.2. Estimated Remuneration for Members of the Board of Directors and the Supervisory Board of the Company for 2026: The estimated remuneration for members of the Board of Directors and the Supervisory Board of the Company for the year 2026 is as follows:

- Board of Directors:
 - + Chairman of the Board of Directors: VND 5,000,000 per month;
 - + Member of the Board of Directors: VND 2,000,000 per person per month.
- Supervisory Board:
 - + Head of the Supervisory Board: VND 2,000,000 per month;
 - + Member of the Supervisory Board: VND 1,500,000 per person per month.

The total estimated remuneration for the Board of Directors and the Supervisory Board for the year 2026 is VND 182,000,000 (inclusive of personal income tax, covering 12 months of remuneration and 01 additional month of remuneration for the Lunar New Year).

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.
Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

6. **Resolution 6:** The General Meeting of Shareholders approves the plan for distribution of profit after corporate income tax for the year 2025 in accordance with the contents of Submission No. 20/2026/TTr-HĐQT dated 09 April 2026 of the Board of Directors of the Company, specifically as follows:

No.	Item	Amount (VND)
I	Undistributed profit after tax	11.958.162.700
1	Accumulated undistributed profit after tax up to the end of the previous period	8.733.814.005
2	Undistributed profit after tax for 2025	3.224.348.695
II	Appropriation to funds in 2026	
1	Reward and welfare fund (10% × profit after tax of 2025)	322.434.870
2	Development investment fund (25% × profit after tax of 2025)	806.087.174
3	Dividend distribution	0
III	Remaining profit	10.829.640.656

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

7. **Resolution 7:** The General Meeting of Shareholders approves the authorization granted to the Board of Directors to decide on the selection of the independent auditing firm to perform the audit of the Company's financial statements for the year 2026, in accordance with the contents of Submission No. 26/2026/TTr-BKS dated 09 April 2026 of the Company's Supervisory Board.

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

8. **Resolution 8:** The General Meeting of Shareholders approves the amendment of the Company's Charter on organization and operation in accordance with the contents of Submission No. 22/2026/TTr-HĐQT dated 09 April 2026 of the Board of Directors.

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

9. **Resolution 9:** The General Meeting of Shareholders fully authorizes the Board of Directors, and permits the Board of Directors to further delegate such authority to the Chairman of the Board of Directors or another member, to review, decide and organize the implementation of all matters approved by the General Meeting of Shareholders, as well as to review and decide on other matters falling within the authority of the General Meeting of Shareholders that arise and require resolution between two annual General Meetings, and to carry out all relevant

procedures in accordance with applicable regulations.

All resolutions and authorizations approved by the 2026 Annual General Meeting of Shareholders shall take effect from the date of approval and shall remain valid for an indefinite duration until otherwise replaced by a subsequent decision of the General Meeting of Shareholders.

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

V. The General Meeting of Shareholders approved the following resolutions with 100% of the voting shares of attending shareholders in favor:

1. **Resolution 1:** Approval of the Board of Management's report on 2025 production and business results and the 2026 plan.
2. **Resolution 2:** Approval of the audited financial statements for 2025.
3. **Resolution 3:** Approval of the Board of Directors' operational report for 2025 and plan for 2026.
4. **Resolution 4:** Approval of the Supervisory Board Report to the 2026 AGM.
5. **Resolution 5:** Approval of remuneration finalization for 2025 and the remuneration plan for 2026:
 - 5.1. Finalization of Remuneration for Members of the Board of Directors and the Supervisory Board of the Company for 2025: The finalized remuneration for members of the Board of Directors ("BOD") and the Supervisory Board ("SB") of the Company for the year 2025 (inclusive of personal income tax, covering 12 months of remuneration and 01 additional month of remuneration for the Lunar New Year) amounts to VND 182,000,000, of which:
 - Total remuneration of the Board of Directors for 2025: VND 117,000,000 per year;
 - Total remuneration of the Supervisory Board for 2025: VND 65,000,000 per year.
 - 5.2. Estimated Remuneration for Members of the Board of Directors and the Supervisory Board of the Company for 2026: The estimated remuneration for members of the Board of Directors and the Supervisory Board of the Company for the year 2026 is as follows:
 - Board of Directors:
 - + Chairman of the Board of Directors: VND 5,000,000 per month;
 - + Member of the Board of Directors: VND 2,000,000 per person per month.
 - Supervisory Board:
 - + Head of the Supervisory Board: VND 2,000,000 per month;
 - + Member of the Supervisory Board: VND 1,500,000 per person per month.The total estimated remuneration for the Board of Directors and the Supervisory Board for the year 2026 is VND 182,000,000 (inclusive of personal income tax, covering 12 months of remuneration and 01 additional month of remuneration for the Lunar New Year).
6. **Resolution 6:** The General Meeting of Shareholders approves the plan for distribution of profit after corporate income tax for the year 2025 in accordance with the contents of Submission No. 20/2026/TTr-HDQT dated 09 April 2026 of the Board of Directors of the Company, specifically as follows:

No.	Item	Amount (VND)
I	Undistributed profit after tax	11.958.162.700
1	Accumulated undistributed profit after tax up to the end of the previous period	8.733.814.005
2	Undistributed profit after tax for 2025	3.224.348.695
II	Appropriation to funds in 2026	
1	Reward and welfare fund (10% × profit after tax of 2025)	322.434.870
2	Development investment fund (25% × profit after tax of 2025)	806.087.174
3	Dividend distribution	0
III	Remaining profit	10.829.640.656

7. **Resolution 7:** The General Meeting of Shareholders approves the authorization granted to the Board of Directors to decide on the selection of the independent auditing firm to perform the audit of the Company's financial statements for the year 2026, in accordance with the contents of Submission No. 26/2026/TTr-BKS dated 09 April 2026 of the Company's Supervisory Board.
8. **Resolution 8:** The General Meeting of Shareholders approves the amendment of the Company's Charter on organization and operation in accordance with the contents of Submission No. 22/2026/TTr-HĐQT dated 09 April 2026 of the Board of Directors.
9. **Resolution 9:** The General Meeting of Shareholders approves the dismissal and additional election of members of the Supervisory Board for the remaining term 2023–2028, as follows:
- Ms. Dang Thi Huong Lan ceases to hold the position of Supervisory Board member of the Company for the term 2023–2028;
 - Ms. Tran Thi Cam Tu is elected as a Supervisory Board member of the Company for the remaining term 2023–2028.
10. **Resolution 10:** The General Meeting of Shareholders fully authorizes the Board of Directors, and permits the Board of Directors to further delegate such authority to the Chairman of the Board of Directors or another member, to review, decide and organize the implementation of all matters approved by the General Meeting of Shareholders, as well as to review and decide on other matters falling within the authority of the General Meeting of Shareholders that arise and require resolution between two annual General Meetings, and to carry out all relevant procedures in accordance with applicable regulations.
- All resolutions and authorizations approved by the 2026 Annual General Meeting of Shareholders shall take effect from the date of approval and shall remain valid for an indefinite duration until otherwise replaced by a subsequent decision of the General Meeting of Shareholders.

VI. APPROVAL OF THE MINUTES AND RESOLUTIONS

Mr. Chu Huy Tung, Head of the Secretariat, read the full Minutes and Resolutions of the 2026 Annual General Meeting of Shareholders.

Voting results:

Affirmative: 5,453,260 voting, equivalent to 100% of the total shares have voting rights attending the meeting.

Negative: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

Abstentions: 0 voting, equivalent to 0% of the total shares have voting rights attending the meeting.

C. CLOSING OF THE GENERAL MEETING

Mr. Nguyễn Văn Thắng - Chairman of the Meeting, delivered the closing remarks.
The 2026 Annual General Meeting of Shareholders of Nghe An Pharmaceutical and Medical Supplies Joint Stock Company concluded at 10 hours 51 minutes on the same day.

CHAIRING COMMITTEE

CHAIRMAN



NGUYEN VAN THANG

MEMBER



TRAN CONG VINH

SECRETARY COMMITTEE

HEAD



CHU HUY TUNG

MEMBER



NGUYEN PHI HAO



**DNA PHARMA**

Chất lượng sống khỏe đẹp hơn

CÔNG TY CP

DƯỢC - VẬT TƯ Y TẾ

NGHỆ AN

NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT - STOCK COMPANY

No. 16 Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

Tel: 0238 384 1642

Enterprise Code: 2900491298

Website: www.dnapharma.com.vn**AGENDA****OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2026****Time:** 08:00 May 05, 2026**Venue:** *Thang Loi Hotel, No. 200 Yen Phu Street, Tay Ho Ward, Hanoi City, Vietnam*

TIME	CONTENTS
08:00 – 08:30	<ul style="list-style-type: none"> - Welcoming guests. - Verifying shareholder eligibility, registering shareholders for the meeting, distributing documents.
08:30 – 08:40	<ul style="list-style-type: none"> - Report on the verification of shareholder eligibility to attend the General Meeting. - Flag ceremony, statement of purpose for holding the General Meeting, opening of the General Meeting. - Introduction of attendees.
08:40 – 08:50	Approval of the Presidium, the Secretariat, and the Vote - Counting Committee. Approval of the General Meeting Agenda and the Rules of Procedure for the General Meeting.
08:50 – 09:00	Report on performance results in 2025 and business plan for 2026.
09:00 – 09:05	The Company's audited financial statements in 2025.
09:05 – 09:15	Report on the Board of Directors' performance results in 2025 and the direction and plan for 2026.
09:15 – 09:25	Report on the activities of the Board of Supervisors in 2025.
09:25 – 09:45	<ul style="list-style-type: none"> - Submission for approval of the remuneration settlement for members of the Board of Directors and Board of Supervisors in 2025 and the remuneration plan for members of the Board of Directors and Board of Supervisors in 2026; - Submission for the after-tax profit distribution plan in 2025; - Submission for selecting an auditing firm for the 2026 financial statements; - Submission for amendments to the Company's Charter of Organization and Operation; - Submission for dismissal and election of additional members of the Board of Supervisors for the remainder of the 2023-2028 term; - Other matters within the scope of authority (if any).
09:45 – 10:00	- Approval of the regulations for the by-election of the Board of Supervisors members for the remainder of the 2023-2028 term; Introduction of the list of candidates and organization of the election.
10:00 – 10:15	Discussion and voting on the General Meeting agenda.
10:15 – 10:30	Break
10:30 – 10:45	Report on the results of the vote count and election
10:45 – 10:55	Adoption of the General Meeting Minutes and Resolutions
10:55 – 11:00	Closing speech of the General Meeting.

**THE ORGANIZING
COMMITTEE OF THE
GENERAL MEETING**



**REPORT ON THE BOARD OF DIRECTORS' PERFORMANCE RESULTS IN 2025 AND
THE DIRECTION AND PLAN FOR 2026**

**To: Shareholders of Nghe An Pharmaceutical Medical Material and Equipment
Joint - Stock Company,**

The Board of Directors ("BOD") of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company ("the Company") respectfully reports to the General Meeting of Shareholders ("GMS") on the Board of Directors' performance results in 2025 and the direction and plan for 2026 with the following main contents:

PART I: BOARD OF DIRECTORS' ACTIVITIES IN 2025

1. Current members of the Board of Directors:

The Board of Directors for the 2023-2028 term consists of 3 members, including the following individuals:

- Mr. Nguyen Van Thang – Chairperson of the Board of Directors;
- Mr. Lang Van Hieu – Member of the Board of Directors;
- Ms. Phan Thi Thu Hien – Member of the Board of Directors.

2. Board of Directors' performance results in 2025:

2.1 The Company's business performance results in 2025:

- Net revenue from sales and services rendered: 141,509,190,051 VND
- Profit before tax: 4,188,886,197 VND
- The Company has made provisions for the Reward and Welfare Fund and the Investment and Development Fund in accordance with the Resolution of the 2025 Annual General Meeting of Shareholders as follows:
 - + Appropriation of reward and welfare fund (10%): 234,591,089 VND;
 - + Appropriation of investment and development (25%): 586,477,722 VND.

2.2 Performance results of the Company's Board of Directors:

The Board of Directors (BOD) operates in compliance with the Enterprise Law, the Charter, and the Company's internal regulations. The BOD holds meetings or seeks written opinions from its members in accordance with the regulations to promptly resolve issues and provide close, timely direction for the Executive Board's activities, ensuring that the Company's production and business operations are carried out in a timely manner without interruption.

The BOD has coordinated closely with the Board of Supervisors (BOS), facilitating their effective control and oversight, while actively supporting the Executive Board in management to jointly achieve the Company's shared goals.

By the end of 2025, the BOD has implemented and completed tasks within its authority as follows:

- Preparations for the Company's 2025 Annual General Meeting of Shareholders:
 - + The BOD coordinated with the Executive Board to carry out procedures for convening and organizing the 2025 Annual General Meeting of Shareholders in accordance with the Company's Charter and legal regulations.
 - + At the 2025 Annual General Meeting of Shareholders (AGM) held on May 29, 2025, the General Meeting of Shareholders approved the main contents as follows: Reports from the Director, the Board of Directors (BOD), Board of Supervisors (BOS) on the performance results in 2024 and plan for 2025; Submissions on the remuneration settlement for the BOD and BOS for 2024, the remuneration plan for 2025, profit distribution plan in 2024, selection of an auditing firm for the 2025 financial statements; and approval of the plan to offer additional shares to existing shareholders to increase the charter capital to 150 billion VND.
 - Pursuant to the Resolution of the Annual General Meeting of Shareholders dated May 29, 2025, the Board of Directors has implemented the public offering of additional shares to existing shareholders to increase the charter capital as follows:
 - (i) Approving the implementation of the plan for a public offering of shares to existing shareholders to increase the charter capital;
 - (ii) Approving the registration dossier for public offering of shares to existing shareholders to increase the charter capital;
 - (iii) Approving the selection of Asean Securities Joint Stock Company as the underwriter and the signing of the underwriting agreement, and the commitment to underwrite the share offering to existing shareholders of the Company with Asean Securities Joint Stock Company.
 - (iv) Approving the detailed plan for using proceeds from the public offering to existing shareholders to increase the charter capital;
 - (v) Approving the timeline for implementation of the offering to existing shareholders;
 - (vi) Approving the results of the share offering to existing shareholders and the plan for distribution of undistributed shares:
- => On March 11, 2026, the Company completed the share offering procedures, with the following results: Number of shares successfully offered: 9,000,000 shares, representing 100% of the total shares on offer; Total proceeds from the offering: 90 billion VND; Charter capital after the completion of the offering: 150 billion VND. The Board of Directors (BOD) has approved the offering results, assigning the Executive Board to carry out necessary procedures to amend the Business Registration Certificate and report the offering results to the State Securities Commission (SSC) as specified.
- => On March 27, 2026, the Company was granted the Business Registration Certificate recording the new charter capital, completing the capital increase in accordance with the resolution approved by the General Meeting of Shareholders.
- The Board of Directors (BOD) has implemented the resolutions passed by the 2025 Annual General Meeting of Shareholders (AGM), including: selecting the auditing firm for the 2025 financial statements; appropriating the Company's reward, welfare, and investment and development funds; etc.
 - The Company's personnel work:
 - + Consolidate the key personnel of the Executive Board; appoint qualified and experienced managers to steer the Company's business operations;
 - + Set up the Raw Material Development Department and strengthen its staff.

+ Approve the decentralization of human resources and financial authority to the Deputy Director;

- Issuance of internal governance regulations/rules for the Company:

+ Approve and issue regulations, rules, organizational structure, and functional duties of departments in compliance with the Company Charter, legal regulations, and practical operational needs, ensuring that the internal regulations are applied consistently and effectively.

+ Adjust the decentralization of human resources management and financial approval authority of the Company.

- Implementation of the Nghe An Pharmaceutical Manufacturing Plant Project at Bac Vinh Industrial Park, Vinh City, Nghe An Province:

+ Pursuant to the 2018 Annual General Meeting (AGM) Resolution, the General Meeting of Shareholders approved the policy to implement the construction investment project of a GMP-standard traditional medicine manufacturing plant at Bac Vinh Industrial Park, Vinh City, Nghe An Province; fully authorized the Board of Directors (BOD) to decide and approve contents related to the Project, direct the implementation of tasks, and complete necessary investment and construction procedures to put the Project into operation in accordance with the law.

+ The Board of Directors has completed the procedures for preparing the investment project, determining the total investment amount, scale, and implementation schedule in accordance with the legal regulations. As of November 2018, the Project was granted the Investment Registration Certificate (IRC), providing the Company with the basis for implementing subsequent procedures.

+ Since 2019, the Company has collaborated with Japanese consultants to research investment in a modern production facility, meeting European, Japanese, and international standards for pharmaceuticals. However, due to the prolonged impact of the Covid-19 pandemic from early 2020 to 2023, the project implementation has been delayed. The Board of Directors and the Executive Board require additional time to study, adjust, and apply advanced, modern technologies during construction and operation to create Vietnamese-branded products.

+ Since 2022, the Company has proceeded with procedures to adjust the Project's objectives, increase its scale and capacity, and amend the implementation schedule to align with the Company's new production and business orientation, allowing additional time to seek partners and contractors for project implementation, as well as to overcome the impacts of the Covid-19 pandemic. On February 24, 2022, the Company received approval from the Management Board of Nghe An South-East Economic Zone for the aforementioned updated and adjustments.

+ Since December 2024, the Company's Board of Directors has initiated procedures to update investor information, adjust the project scale to increase factory capacity in line with the Company's strategic product development orientation, and further adjust the basic construction schedule to bring the project into operation in 2026. As of December 31, 2024, the Company has received approval from the Management Board of Nghe An South-East Economic Zone for the aforementioned updates and adjustments.

+ After working with contractors to prepare cost estimates, finalize construction design drawings, and complete necessary procedures to obtain approval from authorized state agencies, the Board of Directors approved the Master Project Schedule, the procurement and contracting plan, and the construction execution plan for the Plant.

+ During the implementation process, the Executive Board and the Board of Directors (BOD), based on expert advice, will continue to evaluate and review investment items to ensure project efficiency. The BOD will coordinate and direct the Executive Board to expedite progress to bring the Plant into operation soon.



- Other matters within the authority of the Board of Directors.

In 2025, the Company strictly complies with regulations regarding information disclosure, corporate governance reports, and annual reports, ensuring that all operational information is disclosed transparently, thus protecting the rights and interests of the Company and its shareholders.

2.3 Results of monitoring the performance of the Company's Executive Board.:

The Board of Directors (BOD) strictly performs its function of directing and supervising the Board of Management, promptly resolving issues within its authority; and creates favorable conditions for the Board of Management to manage the Company's business operations.

During the task implementation, the Board of Management has always closely followed the Resolutions and targets assigned by the General Meeting of Shareholders (GMS) and the Board of Directors (BOD), and performed its functions and duties within the scope of authority.

In 2025, the Company's operations faced significant challenges due to economic downturns and changes in macro-policies directly impacting our core business. However, the Executive Board made significant efforts, pivoting market and production strategies to gradually regain the competitive edge that constitutes the Company's core strength.

2.4 Board of Directors' Remuneration in 2025:

In compliance with the Resolution of the 2025 Annual General Meeting of Shareholders (AGM), the Company has finalized the total remuneration for the Board of Directors (BOD) for 2023 at 117,000,000 VND (*including personal income tax, 12 months' remuneration, and 01 month's remuneration for the Lunar New Year*). The remuneration structure for the BOD members in 2025 is as follows:

- + Chairperson of the BOD: 5,000,000 VND/month.
- + Member of the BOD: 2,000,000 VND/person/month.

2.5 Reports on transactions with related parties

The list of related persons and related interests has been fully and periodically disclosed by the Company in the Corporate Governance Report in accordance with the legal regulations.

In 2025, there were no transactions between the Company, its subsidiaries, or companies under its control (holding 50% or more of the charter capital) and members of the Board of Directors (BOD) or their related persons; nor were there transactions between the Company and companies in which a BOD member is a founding member or a manager within the last 03 years prior to the transaction.

PART II. DIRECTIONS AND PLANS FOR 2026

1.1. The Board of Directors (BOD) directs and supervises the Executive Board in implementing the 2026 business plan approved by the General Meeting of Shareholders (GMS) based on the following key targets:

- Total revenue: 183.67 billion VND, including:
 - + *Pharmaceutical business revenue: 178.92 billion VND;*
 - + *Revenue from real estate lease agreements: 4.75 billion VND.*
- Profit before tax from core business operations: 10.14 billion VND, including:
 - + *Profit from pharmaceutical manufacturing and business operations: 6.21 billion VND;*
 - + *Profit from real estate lease operations: 3.93 billion VND.*

1.2. The Board of Directors directs and supervises the Executive Board in production, business operations, and investment and development activities as follows:

+ Accelerate the construction progress of the Nghe An Pharmaceutical Manufacturing Plant Project in Bac Vinh Industrial Park, Nghe An Province, to bring it into early operation.

+ Promote the search for and development of new raw materials, aiming to diversify sources for pharmaceutical production. Instruct the Executive Board to research and formulate a plan for cultivating medicinal plants in Nghe An province to create a stable and sustainable supply of raw materials for the Company.

+ Expand business operations and boost market development, particularly in out-of-province markets for company-manufactured products

+ Actively call for and facilitate partners to enter joint ventures for production at the GMP factory.

+ Innovate the product supply mechanism for branches, and by all means, maintain and develop the retail system at the branch level.

1.3. Finance

+ Strengthen debt management and control to avoid capital loss, improve financial regulations, and develop reasonable, cost-effective, and savings-oriented expense norms to enhance the Company's production and business efficiency.

+ Advise on policies for local and inter-provincial sales mechanisms and branch management mechanisms.

1.1. Other works

All departments and units across the Company shall stay united and work together to preserve corporate stability and traditions, foster employee solidarity, and leverage support from authorities and partners; step-by-step overcome challenges, continuously improve infrastructure and working conditions, and enhance welfare to care for the material and spiritual lives of employees.

PART III. CONCLUSION

Above is the Report of the Board of Directors on the evaluation of performance results of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company in 2025, and the orientation of the Board of Directors for 2026. At this General Meeting, the Board of Directors respectfully submits the entire report to the General Meeting of Shareholders for approval.

The Board of Directors (BOD) would like to express our sincere gratitude for the cooperation and support from all shareholders towards the Company in general, and the BOD in particular, throughout 2025. On behalf of the Board of Directors, we wish all shareholders good health, happiness, and success. Wish the General Meeting of Shareholders a great success.

Sincerely,

Recipients:

- Shareholders;
- The Board of Directors, Board of Supervisors;
- Archives: VPTĐ, VT DNA.

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRPERSON



NGUYỄN VĂN THANG



NGHE AN PHARMACEUTICAL
MEDICAL MATERIAL AND
EQUIPMENT JOINT - STOCK
COMPANY

No.: 23 /2026/BC-BKS

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Nghe An, April 9, 2026

REPORT OF BOARD OF SUPERVISORS

Submitted to the 2026 Annual General Meeting of Shareholders

To: The General Meeting of Shareholders of Nghe An Pharmaceutical Medical
Material and Equipment Joint - Stock Company

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to Organizational and Operational Charter of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company;
- Based on the powers and responsibilities of the Board of Supervisors as stipulated in the Organizational and Operational Charter of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company;
- Based on the operational situation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company, the Reports of the Board of Directors and the Executive Board, and the operational situation of the Board of Supervisors in 2025;
- Pursuant to the 2025 Financial Statements audited by Nhan Tam Viet Auditing Company Limited..

The Board of Supervisors of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company would like to hereby report to the General Meeting of Shareholders on the following main points:

I. SUMMARY OF MEETINGS AND ACTIVITIES OF BOARD OF SUPERVISORS IN 2025

1. Regarding the remuneration of the Board of Supervisors 2025:

In 2025, the Annual General Meeting of Shareholders approved the estimated remuneration for the Board of Supervisors. This remuneration will be applied consistently to the members of the Board of Supervisors throughout 2025, specifically:

- Head of Board of Supervisors : 2,000,000 VND/person/month
- Member of Board of Supervisors : 1,500,000 VND/person/month

2. Meetings and activities of the Board of Supervisors in 2025:

In 2025, the Board of Supervisors held meetings to carry out the duties stipulated in the Corporate Charter, including the following key details:

- Monitoring the implementation of the Resolution of the 2025 Annual General Meeting of Shareholders;

- Monitoring the activities of the Board of Directors and the Executive Board;
- Monitoring the compliance with the legal regulations of the State;
- Reviewing the production and business performance of the Company periodically in accordance with the work program of the Board of Supervisors;
- Reviewing and evaluating the reports on implementation of production and business plan, the financial statements, and the management reports of the Company, providing feedback to help the Company promptly address any issues and ensure that the reports and statements are prepared properly, giving a true and fair view of financial position and business operations of the Company.
- Transactions with stakeholders: The Company did not engage in transactions of sale of goods and rendering of services with key managerial members and individuals related to them. As of the end of the fiscal year, the Company has no outstanding debts to key managerial members and individuals related to them.

The inspection and supervision by the members of the Board of Supervisors are carried out continuously and systematically to promptly grasp the operations of the Company, helping the Company to detect and rectify shortcomings in the management, operation and internal control systems.

I. EVALUATION OF PRODUCTION AND BUSINESS OPERATIONS IN 2025

1. Financial position of the Company in 2025

Unit: billion Vietnamese dong

Items	December 31, 2025	December 31, 2024	Difference	Increase / Decrease rate
	(1)	(2)	(3) = (1) - (2)	(4) = (3) / (2)
A. Total assets	124.89	125.12	-0.22	-0.2%
1. Current assets	67.41	73.90	-6.49	-9%
2. Non-current assets	57.48	51.21	6.27	12%
B. Total equity	124.89	125.12	-0.22	-0.2%
3. Liabilities	33.50	36.72	-3.21	-9%
4. Owner's equity	91.39	88.40	2.99	3%

The total assets of the Company as of December 31, 2025 were 124.89 billion VND, a decrease of 0.22 billion VND compared to the beginning of the year. As of December 31, 2025, the balance of current assets was 67.41 billion VND, and that of non-current assets was 57.48 billion VND.

The total equity of the Company as of December 31, 2025 was 124.89 billion VND, a decrease of 0.22 billion VND compared to the beginning of the year. As of December 31, 2025, the balance of liabilities was 33.5 billion VND, and that of owner's equity was 91.39 billion VND.

As of December 31, 2025, the balance of overdue debts was 14.39 billion VND, of which 1.55 billion VND was considered uncollectible debt. Provisions have been made for all uncollectible liabilities.

The financial indicators of the Company remained weak, with a quick ratio of below 0.5, and very low profit levels and returns on net revenue, assets and owner's equity, mainly due to outdated machinery and the resulting difficulty of its products in competing in the market.

2. Evaluation of business results of the Company in 2025

Unit: billion Vietnamese dong

No.	Items	Performed in 2025	Performed in 2024	Difference	Growth rate
		(1)	(2)	(3) = (1) - (2)	(4) = (3) / (2)
1	Net revenue from main production and business operations	141.51	172.13	-30.63	-18%
2	Profit before tax	4.19	3.22	0.97	30%
3	Profit after tax	3.22	2.35	0.88	37%

In 2025, the revenue decreased by 30.63 billion VND, equivalent to an 18% decrease compared to 2024, mainly due to a decrease in revenue from processing and manufacturing. The profit before tax reached 4.19 billion VND, an increase of 0.97 billion VND, equivalent to a 30% increase compared to 2024.

3. Assessment of the financial statements of the Company and the accounting books

The 2025 Financial Statements have been audited by Nhan Tam Viet Auditing Company Limited with a fully unqualified audit opinion.

III. COMPLIANCE WITH THE REGULATIONS OF THE CORPORATE CHARTER, THE RESOLUTIONS OF THE GENERAL MEETING OF SHAREHOLDERS, AND THE LAWS OF THE STATE

In 2025, the Board of Supervisors did not find any unusual signs in the business operations of the Company. All of the activities of the Company complied with the Law on Enterprises, the Corporate Charter and other legal regulations. The Company strictly adhered to the Resolutions of the Board of Directors and the General Meeting of Shareholders.

IV. RESULTS OF MONITORING BOARD OF DIRECTORS, BOARD OF MANAGEMENT AND OTHER BUSINESS MANAGERS

The resolutions of the Board of Directors have been issued in accordance with the authority of the Board of Directors, and the content of these resolutions complies with the Resolutions of the General Meeting of Shareholders, the Law on Enterprises, the Corporate Charter, and other legal regulations.

The Board of Directors held regular and extraordinary meetings chaired by the Chairperson of Board of Directors, regularly inviting the Board of Supervisors to participate in the meetings to implement the resolutions of the General Meeting of Shareholders; discussing and deciding on important issues, and resolving difficulties in production and business operations.

The Board of Supervisors acknowledges that the Board of Directors and the Board of Management have fully fulfilled their management responsibilities in compliance with the Law on Enterprises, the Corporate Charter, the resolutions of the Shareholders' General Meeting, and other legal regulations.

V. ASSESSMENT OF COORDINATION BETWEEN BOARD OF SUPERVISORS, BOARD OF DIRECTORS, BOARD OF MANAGEMENT AND SHAREHOLDERS

In 2025, the Board of Supervisors received close cooperation from the shareholders, the Board of Directors, the Board of Management, and the managers. The Board of Supervisors received all necessary information, reports, and documents for inspection and supervision, and also received personnel assigned to work with it upon the request.

VI. RECOMMENDATIONS

- The Company should make greater efforts in research and development of new products, maximize production capacity at the factory, and expand and develop its products into markets outside the province to develop its brand and bring benefits to the shareholders.
- Develop sales policies and management mechanisms to enhance competitiveness in the retail market and in bidding for contracts with treatment facilities both within and outside the province.
- Strengthen **debt management and inventory control** to avoid capital loss risks, boost sales; and **recover outstanding debts to ensure capital turnover**. Credit limits should be established for each group / category of customers.
- The Company should consider cost reduction options, especially selling expenses, to increase business profitability.
- The Board of Directors and the Executive Board should continue reorganizing the management, production, and personnel structures of departments and branches towards a streamlined and efficient model.
- The Company should implement the pharmaceutical manufacturing plant project in accordance with the project schedule.
- Continue to revise and supplement procedures and regulations on the management and operation of production and business activities, strengthen inspection and supervision of the internal control system to promptly prevent potential risks in accordance with the recommendations and guidance of the Board of Supervisors during its periodic control reviews conducted in 2025 at the Company.

The Board of Supervisors would like to thank the esteemed Shareholders, the Board of Directors, the Board of Management and the Departments / Divisions for creating favorable conditions for the Board of Supervisors to fulfill its duties under the law and the tasks assigned by the General Meeting of Shareholders.

VII. INSPECTION AND MONITORING PLAN OF BOARD OF SUPERVISORS FOR 2026

- Monitoring the compliance with the legal regulations and the Corporate Charter; the implementation of the Resolutions of the General Meeting of Shareholders; and the implementation of the Resolutions, Decisions and Directives of the Board of Directors.

- Conducting inspections and monitoring of the management and operation of the Board of Directors and the Board of Management in accordance with the provisions of the Corporate Charter.
- Monitoring and evaluating the implementation of the business plan, the investment projects, and the asset utilization in 2026.
- Reviewing the quarterly and annual financial statements of the Company. Analyzing and evaluating the financial position and capital management and utilization of the Company.
- Inspecting and evaluating the effectiveness and efficiency of the internal control, internal audit, risk management and early warning systems of the Company; Monitoring and inspecting the implementation of cost-saving measures.
- Coordinating closely with the Board of Directors, the Board of Management, the departments / divisions, and the affiliated units to implement, inspect and monitor the production and business activities of the Company more effectively.

We wish our esteemed Shareholders good health, happiness and success. We wish the General Meeting great success.

Best regards./.

Recipients:

- *General Meeting of Shareholders;*
- *Board of Directors;*
- *Board of Management;*
- *Board of Supervisors.*

**FOR AND ON BEHALF OF BOARD OF
SUPERVISORS**

**By authorization of the Head of Board of
Supervisors**



DAO MANH HUNG



No: 125/2026/BC-DNA

Nghe An, date 09 month 04 2026

**REPORT OF DIRECTOR OF COMPANY ON PRODUCTION AND BUSINESS
RESULTS IN 2025 AND PRODUCTION AND BUSINESS PLAN FOR 2026**

**To: The General Meeting of Shareholders of Nghe An Pharmaceutical Medical Material
and Equipment Joint - Stock Company**

- Pursuant to Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and its relevant guiding documents;
- Pursuant to Organizational and Operational Charter of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (the ‘Company’);
- Based on the actual situation of the Company.

At this General Meeting, on behalf of the Executive Board of the Company, I would like to report on the operational results in 2025 and present to the General Meeting the targets and duties for 2026.

Part I: Report on Business Results in 2025

1. Business results in 2025

With the attention of the Board of Directors of the Company, and the determination of all officials and employees, the Company achieved the following results in 2025:

No.	Items under Resolution	Performance results in 2025 (billion VND)	Compared to the plan for 2025 (%)	Compared to 2024 (%)
1	Net revenue	141.509	67.15%	82.21%
2	Accounting profit before tax	4.188	49.90%	130.08%
5	Payments into State Budget	4.884		
6	Benefits for employees: Social Insurance, Health Insurance, Unemployment Insurance	Full		

2. Evaluation of production and business results in 2025

- Business: The net revenue of the Company in 2025 was projected to reach 141.509 billion VND, achieving 67.15% of the plan and 82.21% of the target for 2024. Reasons for the decrease in net revenue include:
 - The impact of the global economic recession, which has caused difficulties for business operations in general and the pharmaceutical industry in particular.



- Strong fluctuations, scarcity, and disruptions in the supply of raw materials, leading to unmet production targets.
 - Stricter legal regulations related to the pharmaceutical industry
- Profit: The accounting profit before tax in 2025 was 4.188 billion VND, reaching 49.90% of the plan and 130.08% compared to 2024. The increase in the accounting profit before tax is due to: The Company reduced selling expenses and general and administrative expenses in 2025. The selling expenses in 2025 were 17.2 billion VND, a 16% decrease compared to 20.5 billion VND in 2024. The general and administrative expenses were 15.69 billion VND, a 10% decrease compared to 17.4 billion VND in 2024.
 - The Company has established a Raw Material Area Development Department and restructured its personnel to align with the development direction of the Company.
 - The project for construction of office building and plant in Bac Vinh Industrial Park: Having been currently being implemented in accordance with the plan.
 - Implementing the plan for publicly offering shares to existing shareholders to increase charter capital to 150 billion VND.
- + In accordance with the Resolution of the Annual General Meeting of Shareholders dated May 29, 2025 and the Resolutions of the Board of Directors regarding the implementation of the plan for publicly offering shares to existing shareholders to increase charter capital, the Executive Board of the Company, in coordination with the consulting unit – ASEAN Securities Corporation, has submitted documents and explanations to the State Securities Commission (the “SSC”) to register for the additional public offering of shares.
- + On December 26, 2025, the State Securities Commission issued Certificate of Registration for Additional Public Offering of Shares No. 533/GCN-UBCK to the Company.
- + The Company has implemented the following: Announcing the public offering of shares; finalizing the list of shareholders entitled to purchase shares; implementing the detailed procedures and guidance to the shareholders having not yet deposited their shares to register for purchase; transferring the share purchase right; and carrying out other procedures to increase the charter capital of the Company as prescribed.
- + On March 11, 2026, the Company completed the share offering procedures. The offering results were as follows: Number of shares successfully offered: 9,000,000 shares, accounting for 100% of the total shares offered; Total proceeds from the offering: 90 billion VND; Charter capital after completion of the offering: 150 billion VND The Board of Directors approved the offering results and assigned the Executive Board of the Company to carry out the necessary procedures to amend the Business Registration Certificate and to report the offering results to the State Securities Commission as prescribed.
- + On March 27, 2026, the Company was granted a Business Registration Certificate by the Department of Finance of Nghe An Province, recording the new charter capital, completing the capital increase as approved by the General Meeting of Shareholders

Part II: Business Plan Targets and Directions for 2026

1. Production and business plan targets for 2026

- Total revenue: 183.67 billion VND. In which:
 - + Revenue from Pharmaceutical and Medical Equipment business: 178.92 billion VND
 - + Revenue from Real Estate leasing: 4.75 billion VND.
- Profit before tax from main business activities: 10.14 billion VND. In which:

- + Profit from pharmaceutical production and business operations: 6.21 billion VND
- + Profit from real estate leasing operations; 3.93 billion VND.

2. Operational directions for 2026:

- Continue to boost revenue from sale across all segments; assess the difficulties in each segment to develop timely, appropriate and effective solutions.
- For the business segment: Focus on bidding activities. Conduct supplementary bidding for some hospitals in the area to open up new bidding packages;
- Evaluate and select suitable products with high revenue to serve the sales agent system of the branches
- Focus on exploiting core products and market orientation.
 - Encourage and facilitate joint ventures for production at the GMP plant of the Company.
 - Assess the market potential of manufactured goods and the price fluctuations to maintain a reasonable inventory of raw materials, ensuring timely production and increasing competitiveness.
 - Find reasonable solutions and mechanisms to promote sale of manufactured goods at the internal branches and in the provincial markets.
 - Maintain and develop the sales system at the branches, with appropriate policies to sustain and grow it.
- For the production segment:
 - Implement the raw material procurement and strengthen the production to achieve the set production plan.
 - Review to repair and improve the infrastructure and documentation system, for the purpose of the re-evaluation of GMP certification of the Plant.
 - Research and develop the plan for medicinal plant cultivation to crease a stable and sustainable supply of medicinal materials for the Company.
 - Strengthen the management of money and goods at the internal branches.
 - Continue to improve the financial and accounting management.
 - Develop solutions to enhance the rapid recovery of outstanding debts, focusing on sales in the treatment sector and sales outside the province.
- For the Administration and Personnel Affairs:
 - Survey and evaluate land locations for lease, sign contracts, renew contracts, and ensure reasonable prices as prescribed.
 - Review and promote the implementation of a reasonable salary payment plan for officials and employees to maintain key personnel of the Company.
 - Continue to refine the restructuring of some branches to align with the operating conditions of the enterprise.
- Closely monitor and implement the schedule of the pharmaceutical manufacturing plant construction project in Bac Vinh Industrial Park as directed by the Board of Directors and the Chairperson of Board of Directors.



The foregoing is the report on production and business performance in 2025 and operational plan for 2026 of the Company.

I respectfully submitted this document to the General Meeting of Shareholders for consideration and approval.

In-charge Deputy Director



Tran Cong Vinh

NGHE AN PHARMACEUTICAL MEDICAL
MATERIAL AND EQUIPMENT JOINT –
STOCK COMPANY

No.: 21/2026/TTr-HDQT

SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

Nghe An, April 9, 2026

SUBMISSION

(Re: Approval of the remuneration settlement for members of the Board of Directors and Supervisory Board in 2025 and the remuneration plan for members of the Board of Directors and Supervisory Board in 2026)

**To: THE GENERAL MEETING OF SHAREHOLDERS
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND
EQUIPMENT JOINT – STOCK COMPANY**

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by the Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and related guiding documents;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company ("the Company");
- Based on the Board of Directors Resolution No. 15/2026/NQ-HDQT dated March 16, 2026 on the Plan for organizing the Annual General Meeting of Shareholders in 2026;

The Board of Directors of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company respectfully submits to the General Meeting of Shareholders for approval the remuneration settlement for members of the Board of Directors ("BOD") and Board of Supervisors ("BOS") in 2025, and the remuneration plan for members of the BOD and BOS in 2026, specifically as follows:

1. The total remuneration for members of the Board of Directors and Board of Supervisors of the Company for 2025 (including personal income tax, 12 months' remuneration and 1 month's remuneration for the Lunar New Year) is: **182,000,000 VND**.

1.1 Total Remuneration of the Board of Directors in 2025: **117,000,000 VND**.

1.2 Total Remuneration of the Board of Supervisors in 2025: **65,000,000 VND**.

2. The estimated remuneration for members of the Board of Directors and Board of Supervisors of the Company in 2026 is as follows:

2.1 Board of Directors:

+ Chairperson of the Board of Directors: 5,000,000 VND/month.

+ Member of the Board of Directors: 2,000,000 VND/person/month.

2.2 Supervisory Board:

+ Head of the Board of Supervisors: 2,000,000 VND/month.

+ Member of the Board of Supervisors: 1,500,000 VND/person/month.

Total estimated remuneration for the Board of Directors and Board of Supervisors in 2026: **182,000,000 VND** (including personal income tax, comprising 12 months' remuneration and 1 month's remuneration for the Lunar New Year).

Respectfully submit to the General Meeting of Shareholders for consideration and approval. ✓

Recipients:

- The General Meeting of Shareholders; CBTT;
- The Board of Directors and Board of Supervisors;
- Archives: Organization and Administration, the Board of Directors.

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRPERSON



NGUYEN VAN THANG

NGHE AN PHARMACEUTICAL
MEDICAL MATERIAL AND
EQUIPMENT JOINT – STOCK
COMPANY

---o0o---

No.: 20/2026/TTr-HDQT

SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

---o0o---

Nghe An, April 9, 2026

SUBMISSION

(Re: After-tax profit distribution plan in 2025)

To: THE GENERAL MEETING OF SHAREHOLDERS

NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT – STOCK COMPANY

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by the Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and related guiding documents;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company ("**the Company**");
- Based on the Board of Directors Resolution No. 15/2026/NQ-HDQT dated March 16, 2026 on the Plan for organizing the Annual General Meeting of Shareholders in 2026;
- Based on the Company's audited financial statements for 2025.

The Board of Directors ("**BOD**") of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company respectfully submits to the General Meeting of Shareholders the following profit distribution plan for 2025:

Unit: VND


NO.	ITEMS	AMOUNT
I	Undistributed after-tax profit	11,958,162,700
1	Accumulated undistributed after-tax profits at the end of the previous period	8,733,814,005
2	Undistributed after-tax profit for 2025	3,224,348,695
II	Appropriation of funds for 2026	
3.1	Reward and welfare fund (10% * Profit after tax 2025)	322,434,870
3.2	Investment and development fund (25% * Profit after tax 2025)	806,087,174
3.3	Dividend distribution	0
4	Retained earnings	10,829,640,656

Respectfully submit to the General Meeting of Shareholders for consideration and approval. *W*

Recipients:

- *As above;*
- *The Board of Directors, Board of Supervisors;*
- *Archives: Office, the Board of Directors.*

ON BEHALF OF THE BOARD OF
DIRECTORS
CHAIRPERSON *D*
NGUYEN VAN THANG

A red circular stamp is positioned over the signature. The stamp contains the text "M.S.D.N: 2900491" at the top, "CÔNG TY CỔ PHẦN" in the middle, "DƯỢC-VẬT TUYỀN" below it, "NGHỆ AN" in a larger font, and "TỈNH NGHỆ AN" at the bottom. There are two small stars on either side of "NGHỆ AN".



**NGHE AN PHARMACEUTICAL
MEDICAL MATERIAL AND EQUIPMENT
JOINT – STOCK COMPANY**

No.: 26/2026/TTr-BKS

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Nghe An, April 9, 2026

SUBMISSION

(Re: Selecting an auditing firm for the financial statements 2026)

**To: THE GENERAL MEETING OF SHAREHOLDERS
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND
EQUIPMENT JOINT – STOCK COMPANY**

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by the Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and related guiding documents;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company ("the Company");
- Based on the Board of Directors Resolution No. 15/2026/NQ-HDQT dated March 16, 2026 on the Plan for organizing the Annual General Meeting of Shareholders in 2026;

To ensure objectivity and comprehensiveness in the auditing of the Company's business operations, and to enhance transparency and protect shareholders' rights, the Board of Supervisors ("BOS") hereby submits to the Annual General Meeting of Shareholders for 2026 for approval the selection of an auditing firm for the 2026 Financial Statements, as follows:

- Based on the list of auditing firms eligible to provide audit services approved by the Ministry of Finance, along with criteria for quality, reputation, competitive proposals, and support, the Company selects the auditor for the 2026 financial statements.
- Authorize the Company's Board of Directors to select an auditing firm to audit the Company's 2026 financial statements based on the criteria of the list of qualified auditing firms mentioned above.

Respectfully submit to the General Meeting of Shareholders for consideration and approval ✓

Recipients:

- The General Meeting of Shareholders; CBTT;
- The Board of Directors, Board of Supervisors;
- Archives: Organization and Administration, the Board of Directors.

**ON BEHALF OF THE BOARD OF
SUPERVISORS**

DAO MANH HUNG

NGHE AN PHARMACEUTICAL
MEDICAL MATERIAL AND
EQUIPMENT JOINT – STOCK
COMPANY

---o0o---

No.: 22/2026/TTr-HDQT

SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

---o0o---

Nghe An, April 9, 2026

SUBMISSION

Amendments to the Company's Charter of Organization and Operation

To: THE GENERAL MEETING OF SHAREHOLDERS
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT – STOCK COMPANY

- Pursuant to the Enterprise Law No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company ("the Company");
- Pursuant to the Resolution 1678/NQ-UBTVQH15 on the arrangement of commune-level administrative units of Nghe An province ("the Resolution 1678");
- Pursuant to the Decision No. 36/2025/QĐ-TTg on the Vietnamese economic sector classification system (effective from November 15, 2025) ("the Decision 36");
- Pursuant to the Resolution No. 15/2026/NQ-HDQT dated 16/03/2026 of the Board of Directors on the approval of the plan to organize the Annual General Meeting of Shareholders in 2026.

Effective July 1, 2025, the Company's head office address will change as follows: No. 16, **Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province.**

On September 29, 2025, the Prime Minister issued the Decision No. 36/2025/QĐ-TTg on the Vietnamese economic sector classification system, resulting in the removal/change of some business line codes/sectors of the Company.

The Board of Directors respectfully submits to the General Meeting of Shareholders for approval the amendment of the Company's Charter of Organization and Operation ("the Charter") regarding the updating of the registered business line codes/sectors according to the Decision 36 and the Company's head office address due to changes in administrative unit arrangement as follows:

- Amend Clause 3, Article 2 regarding the Company's head office address due to changes in administrative unit arrangement according to the Resolution 1678;
- Amend Clause 1, Article 4 of the Company's Charter regarding the Company's registered business lines to conform with the business codes/sectors that have been changed/removed according to the Decision 36 (as per Appendix 01 on the list of business lines attached to this Submission);
- The General Meeting of Shareholders authorizes the Company's legal representative to review, finalize, and sign the amended Appendix and/or the entire Charter of organization and operation according to the content approved by the General Meeting of Shareholders.

Respectfully submit to the General Meeting of Shareholders for consideration and approval.

Recipients:

- As above;
- The Board of Directors, Board of Supervisors;
- Archives: Office, the Board of Directors.

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRPERSON



NGUYEN VAN THANG



Appendix 01: List of business lines

(Attached to the Submission No. 22/2026/TTr-HDQT dated 09/04/2026)
(Amended and supplemented according to the Decision No. 36/2025/QĐ-TTg of the Prime Minister on the Vietnamese economic sector classification system)

No.	Business lines	Codes
1.	Manufacture of pharmaceuticals, chemical drugs, and medicinal materials Details: Manufacture of medicines, functional foods, fortified foods, chemical drugs, medicinal materials, raw materials for drug production, and processing of medicinal materials	2100 (Chính)
2.	Wholesale of other machinery, equipment and spare parts Details: Wholesale of medical supplies and equipment	4659
3.	Wholesale of other household goods Details: Wholesale of medicines, pharmaceuticals, medicinal herbs, functional foods, fortified foods; Buying and selling cosmetics, cleaning products for personal use	4649
4.	Hotels and similar accommodation services	5510
5.	Other short-term accommodation services	5520
6.	Other remaining professional, scientific and technological activities not classified elsewhere Details: Consulting services for scientific and technical transfer of technology in the field of medicine and pharmaceuticals; consulting on technology transfer for the production of pharmaceuticals and cosmetics; compounding of medicines according to prescriptions.	7499
7.	Other food manufacturing not elsewhere classified	1079
8.	Wholesale of food Details: Wholesale of functional foods and fortified foods specialized stores, pharmacies, and drugstores	4632
9.	Wholesale of other specialized products not classified elsewhere Details: Trading in raw materials and auxiliary materials for pharmaceuticals, pharmaceutical products, chemicals, and medicinal herbs	4679
10.	Retail of medicines, medical devices, cosmetics, and hygiene products Details: Operating pharmacies and drugstores.	4772
11.	Food retail Details: Retail of functional foods and fortified foods in specialized stores, pharmacies, and drugstores	4722
12.	Other remaining business support service activities not classified elsewhere	8299
13.	Warehousing and storage of goods	5210
14.	Real estate business, land use rights owned, used or leased Details: Leasing of offices, assets on land	6810
15.	Manufacture of cosmetics, perfumes, soaps, detergents,	2023

	polishes and sanitary preparations Details: Manufacture of cosmetics, soaps, detergents, polishes and sanitary preparations	
16.	Distilling, refining, and blending spirits Details: Alcohol production	1101
17.	Production of non-alcoholic beverages and mineral water Details: Production of non-alcoholic beverages	1105
18.	Wholesale of beverages Details: Wholesale of wine, beer, and soft drinks	4633
19.	Restaurants and mobile food services Details: Restaurant business	5610
20.	Cultivation of spice, medicinal, and perennial aromatic plants	0128
For conditional business lines, businesses are only permitted to operate when they meet all the conditions stipulated by law.		

NGHE AN PHARMACEUTICAL
MEDICAL MATERIAL AND
EQUIPMENT JOINT – STOCK
COMPANY

---o0o---

No.: 25/2026/TTr-HDQT

SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

---o0o---

Nghe An, April 9, 2026

SUBMISSION

(Re: Dismissal and election of additional members of the Board of Supervisors for the remainder of the 2023-2028 term)

**To: THE GENERAL MEETING OF SHAREHOLDERS
NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT
JOINT – STOCK COMPANY**

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020; amended and supplemented by the Law No. 03/2022/QH15 dated January 11, 2022; Law No. 76/2025/QH15 dated June 17, 2025 and related guiding documents;
- Based on the Charter of Organization and Operation of Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company ("the Company");
- Based on the Resolution No. 15/2026/NQ-HDQT dated 16/03/2026 of the Board of Directors on adopting the Plan for organizing the Annual General Meeting of Shareholders in 2026;
- Based on the resignation letter of Ms. Dang Thi Huong Lan.

The Board of Directors (BOD) has received the resignation letter from Ms. Dang Thi Huong Lan as a member of the Board of Supervisors ("BOS"). In accordance with the Enterprise Law and the Company's Charter, the BOD hereby submits to the General Meeting of Shareholders for approval the following matters:

1. Approval of Ms. Dang Thi Huong Lan's resignation as a member of the Company's Board of Supervisors for the 2023-2028 term;
2. Approval of the election of one additional member to the Board of Supervisors for the remainder of the 2023-2028 term, replacing one member proposed for dismissal.

Based on the nomination documents for the Board of Supervisors' members, respectfully request that the General Meeting proceed with the election of additional members of the Board of Supervisors for the remainder of the 2023-2028 term.

Respectfully submit to the General Meeting of Shareholders for approval. ✓

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRPERSON**

Recipients:

- As above;
- The Board of Directors, Board of Supervisors;
- Archives: Office, the Board of Directors.



NGUYEN VAN THANG